Intratumoral injection reduces toxicity and antibody-mediated neutralization of immunocytokine in a mouse melanoma model

BACKGROUND: Some patients with cancer treated with anticancer monoclonal antibodies (mAbs) develop antidrug antibodies (ADAs) that recognize and bind the therapeutic antibody. This response may neutralize the therapeutic mAb, interfere with mAb effector function or cause toxicities. We investigated...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Immunother Cancer
Main Authors: Baniel, Claire C, Sumiec, Elizabeth G, Hank, Jacquelyn A, Bates, Amber M, Erbe, Amy K, Pieper, Alexander A, Hoefges, Anna G, Patel, Ravi B, Rakhmilevich, Alexander L, Morris, Zachary S, Sondel, Paul M
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Publishing Group 2020
Assuntos:
Immunotherapy Biomarkers
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7594540/
https://ncbi.nlm.nih.gov/pubmed/33115944
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001262
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares